# Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

> **NCT01245556** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 8 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** BMS-908662
- **DRUG:** BMS-908662
- **DRUG:** Ipilimumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT01245556
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2013-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01245556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01245556, "Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01245556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*